Related Experiment Video

Updated: Apr 22, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.5K

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors

Eva M Goetz1, Mahmoud Ghandi2, Daniel J Treacy3

  • 1Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute, Cambridge, Massachusetts.

Cancer Research
|October 17, 2014
PubMed

Insights

Targeted BRAF therapies for melanoma face resistance via MAPK pathway reactivation. Researchers identified ERK1/2 mutations causing resistance, suggesting alternating inhibitor strategies may overcome drug resistance in BRAF-mutant melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Targeted therapies against BRAF(V600) mutations improve outcomes for metastatic melanoma patients.
  • Acquired drug resistance, often through mitogen-activated protein kinase (MAPK) pathway reactivation, limits long-term efficacy.
  • ERK (extracellular signal-regulated kinase) pathway inhibition is a promising therapeutic strategy.

Purpose of the Study:

  • To identify specific mutations in ERK1 and ERK2 that confer resistance to ERK inhibitors or combined RAF/MEK inhibition.
  • To understand the mechanisms of resistance to targeted therapies in BRAF(V600)-mutant melanoma.

Main Methods:

  • Utilized a random mutagenesis screen to generate and identify mutations in ERK1 (MAPK3) and ERK2 (MAPK1).
  • Assessed the impact of identified mutations on resistance to ERK inhibitors and combined RAF/MEK inhibitors.

Main Results:

  • Identified multiple point mutations in ERK1 and ERK2 that confer resistance to either ERK inhibitors or combined RAF/MEK inhibitors.
  • Demonstrated that ERK inhibitor-resistant mutations remained sensitive to RAF/MEK inhibitors, and vice versa.

Conclusions:

  • ERK1/2 mutations are a mechanism of acquired resistance to targeted melanoma therapies.
  • Alternating regimens of RAF/MEK and ERK inhibitors may represent a viable strategy to circumvent drug resistance.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

940
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K